Showing 1716 results
-
Press release /Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +…
-
Press release /Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per updated…
-
Press release /Filings supported by pivotal ELARA trial, where treatment with Kymriah showed robust response rates and remarkable safety profile in adult patients with relapsed or refractory (r/r) follicular…
-
Press release /New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact…
-
Ad hoc release /Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with…
-
Press release /Decision brings hope of longer and better life with fewer hospitalizations for millions of Europeans with symptomatic chronic heart failure with reduced ejection fraction Entresto is the…
-
Press release /Collaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…
-
Press release /Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances…
-
Press release /Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG…
-
Press release /Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to…